Pain is one of the most common reasons people visit the hospital. For many years, strong painkillers called opioids were used to treat severe pain. However, these drugs can have serious side effects and problems. Because of this, scientists are working on a safer option called non-opioid pain relievers.
Recently, a new drug, “Suzetrigine,” has been introduced. It works differently by blocking pain signals in the nerves before they reach the brain, whereas opioids usually work on the brain. Thus, it can reduce pain without causing addiction.
Suzetrigine :
Brand name: Journavx. It is a first-in-class, non-opioid oral analgesic approved by the FDA on January 30, 2025. It selectively inhibits sodium channels in the peripheral nervous system, blocking pain signals without the addiction risk, nausea, or dizziness associated with opioids.
Side Effects: dizziness, constipation, or headache, as well as itching, muscle spasms, and rash.
Benefits
- Non-Opioid: Acts on peripheral neurons, bypassing the central nervous system mechanisms that cause addiction.
- Efficacy: Demonstrated effectiveness in reducing pain intensity following surgeries such as abdominoplasty and bunionectomy.
- Convenience: Taken orally as a pill.
Read more: FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain | FDA
MBH/PS
high addiction potential. Journavx, being a non-opioid alternative with similar efficacy and lower addiction risk, is a great option for pain management. Thanks for sharing this.